Interim study of the medical response to COVID-19

Montana's SJ 50 is a joint resolution requesting an interim study on the effects of medical treatments used during the COVID-19 pandemic. It directs a committee or staff to examine the short- and long-term impacts of the COVID-19 vaccine, remdesivir, dexamethasone, and other treatments, including the benefits of ivermectin and outcomes related to Montana's Right to Try Act for "long COVID" and vaccine-related health issues. The study must conclude by September 15, 2026, and report findings to the 70th Legislature. As a procedural resolution (not a law), it does not change existing policies but seeks to review past medical responses. The resolution was referred to committee but died there in May 2025.